Beijing: China has five vaccines for Novel Coronavirus currently undergoing phase III clinical trials in some foreign countries, a Foreign Ministry spokesperson said on Wednesday.
Spokesperson Zhao Lijian told a news briefing that since the outbreak of COVID-19, the Chinese government adopted five technological approaches to develop COVID-19 vaccines, namely inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, vaccines using attenuated influenza viruses as vectors, and nucleic acid vaccines.
China is conducting research and development in an orderly manner, said Lijian, adding that the country currently has five vaccines for COVID-19 that are currently undergoing phase III clinical trials in the United Arab Emirates, Brazil, Pakistan and Peru, and some other vaccines that are undergoing phase I and II clinical trials.
China has always actively carried out international vaccine co-operation through multilateral and bilateral channels and maintained close communication and cooperation with international organisations such as the World Health Organisation (WHO), the Global Alliance for Vaccines and Immunisation, and the Coalition for Epidemic Preparedness Innovations, he said.
The Spokesperson further said that China participated in the WHO-sponsored Access to COVID-19 Tools (ACT) Accelerator initiative, and joined the COVAX facility to promote the fair distribution of vaccines and ensure that vaccines were provided to developing countries.